AMAG Pharmaceuticals (NASDAQ: AMAG) was downgraded by research analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a report released on Thursday. They currently have a $17.00 target price on the stock, down from their previous target price of $21.00.
Shares of AMAG Pharmaceuticals traded down 2.49% during mid-day trading on Thursday, hitting $13.33. AMAG Pharmaceuticals has a one year low of $12.65 and a one year high of $19.62. The company’s market cap is $284.7 million.
AMAG Pharmaceuticals last posted its quarterly earnings results on Tuesday, May 1st. The company reported ($0.58) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.63) by $0.05. AMAG Pharmaceuticals’s revenue was up 15.7% compared to the same quarter last year. Analysts expect that AMAG Pharmaceuticals will post $0.31 EPS next quarter.
Separately, analysts at Jefferies Group (NYSE: JEF) reiterated an “underperform” rating on shares of AMAG Pharmaceuticals in a research note to investors on Tuesday, March 6th.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which utilizes the technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and imaging agents to aid in the diagnosis of cancer and cardiovascular disease.